Recent Progress in Peptide-Based Molecular Probes for Disease Bioimaging
Y Xu, J Chen, Y Zhang, P Zhang - Biomacromolecules, 2024 - ACS Publications
Recent strides in molecular pathology have unveiled distinctive alterations at the molecular
level throughout the onset and progression of diseases. Enhancing the in vivo visualization …
level throughout the onset and progression of diseases. Enhancing the in vivo visualization …
[HTML][HTML] Structured reporting of computed tomography in the staging of neuroendocrine neoplasms: a Delphi consensus proposal
Background Structured reporting (SR) in radiology is becoming increasingly necessary and
has been recognized recently by major scientific societies. This study aims to build …
has been recognized recently by major scientific societies. This study aims to build …
Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim …
Z Lin, W Zhu, J Zhang, W Miao, S Yao… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The current study aimed to compare 68Ga-NODAGA-Cpa-cyclo (d-Cys-amino-Phe-
hydroorotic acid-d-4-amino-Phe (carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH2 (JR11) and 68Ga …
hydroorotic acid-d-4-amino-Phe (carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH2 (JR11) and 68Ga …
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
D Kersting, P Sandach, M Sraieb… - Journal of Nuclear …, 2023 - Soc Nuclear Med
PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan
(SSO-120, previously OPS-202) could offer accurate tumor detection and screening for …
(SSO-120, previously OPS-202) could offer accurate tumor detection and screening for …
Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability
M Loft, EA Carlsen, CB Johnbeck, CV Jensen… - Molecular Imaging and …, 2022 - Springer
Purpose Patients with neuroendocrine neoplasms (NEN) engage in lifelong follow-up with
frequent somatostatin receptor PET, eg.[64Cu] Cu-DOTATATE PET, and continued …
frequent somatostatin receptor PET, eg.[64Cu] Cu-DOTATATE PET, and continued …
[HTML][HTML] A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic …
CG Miller, H Grønbæk, I Virgolini, A Kjaer, P Terve… - EJNMMI research, 2021 - Springer
Background 68 Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist
exhibiting higher tumour-to-background ratios and sensitivity compared to 68 Ga-DOTATOC …
exhibiting higher tumour-to-background ratios and sensitivity compared to 68 Ga-DOTATOC …
[HTML][HTML] Frontrunners in Next-Generation Radiotherapeutics
C Barton - Pharmaceutical Technology, 2023 - pharmtech.com
Ariceum Therapeutics, a private biotechnology company, based in Germany, is focused on
developing novel drugs for systemic targeted radiation therapy (STRT) for hard-to-treat …
developing novel drugs for systemic targeted radiation therapy (STRT) for hard-to-treat …
Frontrunners in Next-Generation Radiotherapeutics: New radiotherapeutic agents are making headway in hard-to-treat cancers.
C Barton - Pharmaceutical Technology Europe, 2023 - go.gale.com
Ariceum Therapeutics, a private biotechnology company, based in Germany, is focused on
developing novel drugs for systemic targeted radiation therapy (STRT) for hard-to-treat …
developing novel drugs for systemic targeted radiation therapy (STRT) for hard-to-treat …